Objectives: The purpose of the study was to evaluate the efficacy and safety of the entirely subcutaneous implantable cardioverter-defibrillator (S-ICD). Background: A new entirely S-ICD has been introduced, that does not require lead placement in or on the heart. The authors report the largest multicenter experience to date with the S-ICD with a minimum of 1-year follow-up in the first 118 Dutch patients who were implanted with this device. Methods: Patients were selected if they had a class I or IIa indication for primary or secondary prevention of sudden cardiac death. All consecutive patients from 4 high-volume centers in the Netherlands with an S-ICD implanted between December 2008 and April 2011 were included. Results: A total of 118 patients (75% males, mean age 50 years) received the S-ICD. After 18 months of follow-up, 8 patients experienced 45 successful appropriate shocks (98% first shock conversion efficacy). No sudden deaths occurred. Fifteen patients (13%) received inappropriate shocks, mainly due to T-wave oversensing, which was mostly solved by a software upgrade and changing the sensing vector of the S-ICD. Sixteen patients (14%) experienced complications. Adverse events were more frequent in the first 15 implantations per center compared with subsequent implantations (inappropriate shocks 19% vs. 6.7%, p = 0.03; complications 17% vs. 10%, p = 0.10). Conclusions: This study demonstrates that the S-ICD is effective in terminating ventricular arrhythmias. There is, however, a considerable percentage of ICD related adverse events, which decreases as the therapy evolves and experience increases.

ICD, heart rhythm disturbances, implantable cardioverter-defibrillator, subcutaneous, ventricular arrhythmia
dx.doi.org/10.1016/j.jacc.2012.06.053, hdl.handle.net/1765/37469
Journal of the American College of Cardiology
Erasmus MC: University Medical Center Rotterdam

Olde Nordkamp, L.R.A, Dabiri Abkenari, L, Boersma, L, Maass, A.H, de Groot, J.R, van Oostrom, A.J.H.H.M, … Knops, R.E. (2012). The Entirely Subcutaneous Implantable Cardioverter-Defibrillator. Initial Clinical Experience in a Large Dutch Cohort. Journal of the American College of Cardiology, 60(19), 1933–1939. doi:10.1016/j.jacc.2012.06.053